Elena Dragun, MD
Pediatrics · Elizabeth, NJNPI 1467413583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among pediatrics clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$959
- Boehringer Ingelheim$667
- Kowa Pharmaceuticals America, Inc.$591
- AbbVie$501
- Novo Nordisk$349
- Lilly USA, LLC$328
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,737100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $959 |
| Boehringer Ingelheim | 16 | $667 |
| Kowa Pharmaceuticals America, Inc. | 29 | $591 |
| AbbVie(2 entities) | 39 | $501 |
| Novo Nordisk | 22 | $349 |
| Lilly USA, LLC | 23 | $328 |
| Amgen(2 entities) | 10 | $140 |
| Amarin Pharma, Inc. | 10 | $138 |
| Abbott | 4 | $137 |
| Merck | 9 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Genentech USA, Inc. | 9 | $121 |
| Sanofi-aventis U.S. LLC | 8 | $116 |
| Johnson & Johnson | 5 | $71 |
| Pfizer | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Nestle Healthcare Nutrition Inc. | 4 | $56 |
| Bayer | 2 | $37 |
| Exact Sciences | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $18 |
| Alk-abello, Inc | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,737 in reported general payments places this provider in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $67,084 |
| OzempicSemaglutide | 33 | $48,744 |
| RybelsusSemaglutide | 20 | $34,873 |
| FarxigaDapagliflozin Propanediol | 33 | $32,152 |
| EliquisApixaban | 23 | $29,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $20,261 |
| LinzessLinaclotide | 13 | $19,722 |
| VascepaIcosapent Ethyl | 14 | $12,912 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,936 |
| Rosuvastatin Calcium | 166 | $5,314 |
| Ezetimibe | 65 | $3,210 |
| Olmesartan Medoxomil | 26 | $2,370 |
| Valsartan | 59 | $2,337 |
| Atorvastatin Calcium | 149 | $2,146 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 26 | $1,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $349 | $83,61753 claims |
| Boehringer IngelheimJardiance | $667 | $67,08445 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $959 | $52,41360 claims |
| PfizerEliquis | $66 | $29,04923 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $501 | $22,70742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,890 pediatrics providers in New Jersey.
Other pediatrics in Elizabeth
- Steven MateretskyHackensack$290K
- Sara RaymondMorristown$288K
- Andrew MulbergCamden$264K
- Bram GreenbergLakewood$200K
- David ApelianBoonton$149K
- Christopher AmatoGibbsboro$34K
- Syeda Amna HusainMarlboro$27K
- Nika DouvikasJersey City$27K
- Melanie DegliuominiHackensack$17K
- Alexandra LaurenzanoRiver Vale$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.